INTRODUCTION
The association between Zika virus (ZikV) infection and acute neurological disorders such as Guillain-Barre syndrome (GBS) and microcephaly was declared a public health emergency of international concern by the World Health Organization [WHO] (1) .
Zika, an arbovirus of the Flaviviridae family, first isolated from a Rhesus monkey obtained from the Zika forest of Uganda in 1947, caused human infections and minor outbreaks characterized by a mild febrile illness first in Uganda and Tanzania in 1952 and then across Africa and Asia (2, 3) . The 2007 Yap Island outbreak was the first reported Zika outbreak outside Africa and Asia (4) . French Polynesia had an increase in GBS during a Zika outbreak which began October 2013; 42 cases in seven months and all were Zika-virus IgM, IgG and/or RNA positive [OR 34.1, p < 0.0001] (5).
Jamaica first reported Zika virus infection in January 2016 and documented autochthonous transmission in May 2016. As of September 2, 2016, 5299 suspected and 92 confirmed Zika infections and as of September 5, 111 suspected GBS cases were reported (6) .
Guillain-Barre syndrome cases were anecdotally infrequent in Jamaica. A young female with flaccid quadriparesis and bulbar weakness with the acute motor-sensory axonal GBS variant, occurring three weeks post a gastrointestinal illness and who later died from complications has been described (7). Guillain-Barre syndrome is an acute inflammatory polyradiculoneuropathy commonly occurring two to three weeks after an infection as a result of antibodies directed at the infectious agent cross-reacting with peripheral nerve epitopes (8) . Guillain-Barre syndrome classically presents as rapidly ascending areflexic limb weakness with mild sensory changes and occasional bulbar and respiratory muscle weakness though there are several described variants. Clinical diagnosis is supported by cyto-albumin dissociation characterized by an elevated cerebrospinal fluid (CSF) protein in the absence of an elevated cell count greater than 50 cells per microlitre and neurophysiology which can further classify GBS as a demyelinating or an axonal polyneuropathy (9) . Immunoglobulin (IVIg) and plasma exchange are equally effective and either are recommended for non-ambulatory patients and progressively worsening ambulatory patients who are within 28 days of neuropathic onset (10, 11) . At six and 12 months about 80 and 84% of persons are ambulatory (12) .
Other reported neurological syndromes include transverse myelitis (TM), meningoencephalitis (ME), encephalitis (EN) and acute disseminated encephalomyelitis [ADEM] (13−16), therefore, a broad operational definition is warranted to describe Zika outbreak associated neurological syndromes. The demographic, clinical and laboratory features of Zika outbreak associated neurological syndromes at the KPH and the early experience of their treatment and outcomes are described.
SUBJECTS AND METHODS
Men and women aged 12 years and over admitted to Internal Medicine and/or Neurology services between April to September 2016 at the KPH and meeting the criteria for a Zika outbreak associated neurological syndrome were identified for retrospective medical record review.
Operational definitions
Zika outbreak associated neurological syndrome: neurological syndrome characterized by acute/sub-acute monophasic bilateral areflexic/hyporeflexic limb weakness and/or sensory impairment with/without cranial nerve, meningeal, myelopathic or encephalopathic abnormalities, with/without antecedent viral symptoms, without another more reasonable explanation during the recent Zika outbreak.
Guillain-Barre syndrome or GBS: acute or sub-acute monophasic autoimmune polyradiculoneuropathy meeting the Brighton Criteria (17) .
Suspected Zika virus infection (and Zika symptoms): rash or elevated body temperature > 37.2°C with one or more of the following symptoms (not explained by other medical conditions): arthralgia, myalgia, non-purulent conjunctivitis or conjunctival hyperaemia, headache or malaise; in someone who resides in or has visited epidemic or endemic areas within two weeks prior to the onset of symptoms; Post-viral neurological syndromes and autoimmune syndromes are to be considered suspected cases of Zika virus infection.
Confirmed Zika virus infection: A suspected case with laboratory positive result for the specific detection of Zika virus.
Measurements
Parameters assessed include age, gender, time to neuropathic symptoms from viral symptom onset, time to nadir of neurological symptoms, viral symptoms, neurological signs, CSF 
Statistical analyses
The SPSS software v. 22 was used to determine descriptive statistics such as means and proportions for demographic, clinical and laboratory features. The Chi-squared test was used to assess the association between exposure variables, for example dysautonomia and risk for an adverse outcome such as death or ICU admission.
RESULTS
Thirty-five met the criteria for inclusion and 25 medical records were reviewed. Frequency of specific neurological syndromes and positive viral serology are outlined in Table 1. or paraplegia (14%). The distribution of weakness was proximal more than distal in most patients (81%) with significant vibratory impairment observed to the knees and above, often to the high thoracic level (86%). Eight per cent had pure sensory symptoms with ataxia. Sixty-seven per cent had features of dysautonomia characterized by persistent tachycardia, new or worsening hypertension and blood pressure lability with a trend towards significance for death (p = 0.074).
Systematic clinical examination for mental status changes, meningeal signs and a sensory level corroborated by demyelination on brain and/or spinal cord MRI or, as appropriate, evidence of a CSF pleiocytosis identified those cases of transverse myelitis (TM), meningoencephalitis (ME) and acute disseminated encephalomyelitis (ADEM). The four cases thus identified also had initial and persistent clinical features of a flaccid quadriparesis and cranial neuropathies.
Nerve conduction studies in four GBS patients all showed an acute demyelinating neuropathy. Eighty-seven per cent of 15 lumbar punctures demonstrated cyto-albumin dissociation. Despite initial CSF pleiocytosis for patients with ME and ADEM, gram stain and cultures were negative.
Nine GBS patients (5 men with average age 53 years; 4 women with average age 45.8 years), 1 of 2 with ME and both cases of TM and ADEM had respiratory muscle failure and were admitted to the ICU for mechanical ventilation. Twentythree out of 25 patients received IVIg; two with purely sensory GBS improved and were ambulatory at discharge without IVIg. Patients with TM and ADEM were also treated with intravenous corticosteroids and empirical anti-meningitic doses of antibiotics were given to both patients with ME. All had physiotherapy, nutritional support, venous thromboembolism prophylaxis and psychosocial support. Four patients died (three men whose ages were 61, 64 and 78 years).
DISCUSSION
Zika outbreak neurological syndromes were commonly associated with antecedent viral symptoms but only 2 had evidence of acute Zika infection. Potential reasons for this include inadequate or late sample collection, poor sample handling as well as the narrowness of the window for identifying the virus in body fluids. Still possible is that not all are Zika-related and may be due to other viruses, including influenza especially (H1N1), Chikungunya and Dengue which can produce similar neurological syndromes (18) . 2 GBS patients were positive for acute Dengue IgM and another had positive IgM for Dengue and Chikungunya.
Interesting to note are the mixed neurological pictures seen in a minority of the patients with features typical of GBS and another neurological syndrome such as TM or ME. One of two patients with ME had positive Zika IgM.
The association between dysautonomia and risk of death (p = 0.074) will require further data collection or data pooling to confirm an association.
In this epidemic, cases of GBS had an increased tempo from onset to nadir, more frequent bulbar and respiratory Men and women were affected almost equally (13 vs 12); on average, men were older than women (46.6 vs 38.8 years). Seventeen of 21 GBS cases reported symptoms consistent with Zika infection, with headache (9), vomiting (9), rash (8), fever (6) and conjunctivitis (4) being the most common despite only two with positive Zika IgM serology (Table 1) and no Zika positive RT-PCR. Guillain-Barre syndrome occurred on average four days from onset of viral symptoms and time to clinical nadir averaged 7.15 days from neuropathic onset. Eight patients had a para-infectious onset with neurological symptoms on day 1 of viral symptoms. Clinical features of GBS were: flaccid quadriparesis or quadriplegia (76%), dysphagia (62%), dysphonia (67%), bilateral facial weakness (71%) and flaccid paraparesis muscle failure requiring ICU admission and increased mortality, 16% vs 4% for classic post-infectious GBS (12) . The cooccurrence of acute viral symptoms with the evolving neurological syndrome suggest that mechanisms other than post-infectious auto-immune mechanisms (8) including direct viral toxicity may contribute to this unique temporal relationship (5) .
Men with GBS were older than average and appeared to have greater mortality (three of four deaths were men over age 60 years). Although preliminary, age and male gender may be important risk factors for more severe outcomes. Viral persistence in seminal fluid may conceivably place older men at greater risk of more severe disease (19) .
Conversely, two patients with pure sensory GBS did not need IVIg for recovery. Anecdotal reports from outpatient practices suggest that the sensory variant, typically manifested as paraesthesia and/or burning/cold dysaesthesia may be more common than clinically reported.
Late identification of neurological complications and consequent delays in initiating disease-modifying treatment (IVIg), though not specifically described here, along with a potentially uniquely more severe phenotype of GBS and other Zika outbreak associated neurological syndromes may have accounted for the greater overall morbidity and mortality in our patients. Knowledge of these neurological complications, early syndromic classification, in particular of the most common neurological complication, GBS, with early initiation of IVIg treatment may alter the clinical trajectory of these patients, reducing their maximum deficits and need for ICU care and thus, may reduce overall healthcare costs.
CONCLUSION
The Zika outbreak has brought a range of acute neurological complications many of which are usually rare and/or unusual in clinical phenotype. As the epidemic evolves, final definitive ascertainment of the overall risk of GBS or other neurological complications will be clearer when the entire island has eventually been exposed and with systematic research. Meanwhile, we hope that sharing our early clinical experiences will augment early diagnosis, reduce treatment delays and reduce morbidity and mortality of Zika outbreak associated neurological syndromes in Jamaica and beyond our shores.
